-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chuangsheng Group, an international biopharmaceutical company in the clinical stage with the ability to integrate the entire process of biopharmaceutical R&D, clinical and process development and production, announced that it has completed TST001, a human source targeting Claudin 18.
2 (CLDN18.
2) Monoclonal antibody, combined with oxaliplatin and capecitabine, was administered to the first patient in a phase I clinical study of first-line locally advanced unresectable or metastatic gastric cancer
.
TST001 is a second-generation recombinant humanized monoclonal antibody candidate drug targeting CLDN18.
2 independently developed by Chuangsheng Group through its immune tolerance barrier breakthrough technology platform
.
TST001 can specifically bind to CLDN18.
"CLDN18.
2 has been shown to be abnormally expressed in many types of cancers, including gastric cancer, pancreatic cancer, and esophageal cancer
.
At present, the first-in-class drug IMAB362 is used in the FAST Phase II study of first-line gastric cancer patients with high expression of CLDN18.
Dr.
Shi Ming, Executive Vice President, Head of Global R&D and Chief Medical Officer of Chuangsheng Group, said: “Gastric cancer is a high incidence tumor species in China and Asia
.
Approximately 70% of gastric cancer patients express CLDN18.
